PHARMA LENS: GLP-1 fallout, insurance coverage shifts, and the metabolic debt of the retail food pivot.
Cassandra Protocol
Accessing the Cassandra Archive for 22 September 2026. We pull the ledger on Viking Therapeutics and Hims & Hers, exposing the structural deficit and metabolic tollbooth of the modern telehealth industry.
Pharmaceutical Industry
The compounded GLP-1 hustle is over. As Hims & Hers pivots to branded Wegovy, patients face severe price hikes while competitors like Amazon and Eli Lilly undercut the market. Welcome to the biological ransom.
Telehealth
A forensic audit of the Hims & Hers telehealth model following the FDA's termination of the semaglutide shortage. Examining margin collapse, unit economics, and the financial reality behind the GLP-1 distribution pivot.
Eli Lilly
Live from the archive on 20 September 2026. File S01E98 investigates Eli Lilly and the diabesity ecosystem, tracking how a pharmaceutical giant turned the absence of hunger into a highly collateralized commodity.
Eli Lilly
Eli Lilly isn't just selling weight-loss drugs; they're running a subscription model for human biology. A critical look at the compounding pharmacy black market, regulatory gridlock, and the cynical reality of lifelong dependency pricing.
Eli Lilly
An analytical breakdown of Eli Lilly's GLP-1 portfolio, examining how chemical appetite suppression is driving a macroeconomic migration of capital from the global food industry to the pharmaceutical sector amid shifting Medicare coverage.
Novo Nordisk
File open 18 September 2026: Novo Nordisk / Diabesity Ecosystem.
Novo Nordisk
Marcus on Novo Nordisk: the spin vs the invoice.
Novo Nordisk
Forensic audit of Novo Nordisk under Diabesity Ecosystem.